Document Type
Article
Publication Date
4-29-2025
Abstract
Thrombocytopenia is a common challenge in the neonatal intensive care unit, traditionally managed with platelet transfusions. However, transfusions are associated with significant risks, including increased mortality and neurodevelopmental impairment. This case series highlights the use of romiplostim, a thrombopoietin receptor agonist, in three neonates with thrombocytopenia. Each case demonstrated notable improvements in platelet counts without adverse events, reducing dependency on transfusions. These findings underscore romiplostim's potential as a safer alternative for managing neonatal thrombocytopenia. This report advocates for further research to explore romiplostim's efficacy and safety in this vulnerable population, emphasizing its promise in improving neonatal outcomes.
Keywords
neonate, romiplostim, thrombocytopenia, TPO-RA
Language
English
Publication Title
Pediatric Blood and Cancer
Rights
© 2025 The Author(s). Pediatric Blood & Cancer published by Wiley Periodicals LLC. This is an open access work distributed under the terms of the Creative Commons Attribution-Non-Commercial (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Recommended Citation
Zeno, R.N., Awad, S. and Lesmana, H. (2025), Utility and Safety of Romiplostim as an Alternative to Platelet Transfusion for Neonates. Pediatr Blood Cancer, 72: e31753. https://doi.org/10.1002/pbc.31753
Manuscript Version
Final Publisher Version